Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews
Tais F. Galvao, Maria Elizete A. Araujo, Anderson P. Penha and Marcus T. Silva
Affiliation: Faculty of Medicine, University of Brasilia, P.O. Box 4472, CEP 70904-970. Brasilia, DF, Brazil.
Keywords: Chronic renal insufficiency, hydroxymethylglutaryl-CoA reductase inhibitors, kidney diseases, review
Objective: To assess the efficacy of statin therapy on early stage chronic kidney disease through an overview of
Methods: We searched for systematic reviews of randomized clinical trials (RCT) on MEDLINE, Embase, Cochrane
Library, CRD, and Scopus. Independent reviewers selected the studies and extracted the relevant data. We critically
appraised the included systematic reviews with the AMSTAR tool and presented the available data in the studies.
Results: From 731 retrieved records, we included three systematic reviews. Statins reduced the risk of mortality for all
causes and for cardiovascular causes in patients with early stage chronic kidney disease as compared to the control (highquality
evidence). Statins also reduced the incidence of any myocardial infarction, non-fatal myocardial infarction, and
stroke (moderate- to high-quality evidence). No differences were observed between statins and control upon the incidence
of end-stage renal disease or on the outcomes assessed in patients with coronary artery disease and diabetes.
Conclusion: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney
disease and should be considered for such individuals who also present hyperlipidemia.
Rights & PermissionsPrintExport